The present case indicated that the use of an anti-PD-1 monoclonal antibody combined with SBRT might be a promising therapeutic strategy for recurrent esophageal squamous cell carcinoma even in patients with negative PD-L1 expression. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.